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Background: Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition predisposing 
individuals to chronic obstructive pulmonary disease (COPD). The treatment is generally 
extrapolated from COPD unrelated to AATD; however, most COPD trials exclude AATD 
patients; thus, this study sought to systematically review AATD-specific literature to assist 
evidence-based patient management.
Methods: Standard review methodology was used with meta-analysis and narrative synthesis 
(PROSPERO-CRD42015019354). Eligible studies were those of any treatment used in severe 
AATD. Randomized controlled trials (RCTs) were the primary focus; however, case series and 
uncontrolled studies were eligible. All studies had 10 participants receiving treatment or usual 
care, with baseline and follow-up data (3 months). Risk of bias was assessed appropriately 
according to study methodology.
Results: In all, 7,296 studies were retrieved from searches; 52 trials with 5,632 participants 
met the inclusion criteria, of which 26 studies involved alpha-1 antitrypsin augmentation and 
17 concerned surgical treatments (largely transplantation). Studies were grouped into four 
management themes: COPD medical, COPD surgical, AATD specific, and other treatments. 
Computed tomography (CT) density, forced expiratory volume in 1 s, diffusing capacity of 
the lungs for carbon monoxide, health status, and exacerbation rates were frequently used as 
outcomes. Meta-analyses were only possible for RCTs of intravenous augmentation, which 
slowed progression of emphysema measured by CT density change, 0.79 g/L/year versus 
placebo (P0.002), and associated with a small increase in exacerbations 0.29/year (P0.02). 
Mortality following lung transplant was comparable between AATD- and non-AATD-related 
COPD. Surgical reduction of lung volume demonstrated inferior outcomes compared with 
non-AATD-related emphysema.
Conclusion: Intravenous augmentation remains the only disease-specific therapy in AATD 
and there is evidence that this slows decline in emphysema determined by CT density. There is 
paucity of data around other treatments in AATD. Treatments for usual COPD may not be as 
efficacious in AATD, and further studies may be required for this disease group.
Keywords: alpha-1 antitrypsin deficiency, treatment, emphysema, transplantation
Introduction
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that predisposes 
patients to chronic obstructive pulmonary disease (COPD)1 albeit with consider-
able variability of clinical phenotype.2 The spirometric diagnosis of AATD-related 
COPD and “usual” (unrelated to AATD) COPD is identical, but it manifests at a 
younger age. Not all subjects develop pulmonary disease and those who do vary in 
presentation and subsequent decline.3 The first subjects observed with low alpha-1 
antitrypsin (AAT) levels were young smokers with basal panacinar emphysema,4 a 
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finding which remains a typical AATD presentation,5,6 though 
bronchiectasis, neonatal jaundice, liver cirrhosis, and pan-
niculitis may be seen.6–9
The most well-known polymorphisms (protease inhibi-
tor [Pi] Z allele), present in the homozygous state in around 
1/5,000 European Caucasians,10 arise from a point mutation 
in SERPINA1 and result in a change to AAT structure, caus-
ing polymerization, accumulation in hepatocytes, and thus 
reduced circulating level of AAT.11 Homozygous “Z” patients 
have an AAT level of 1.3–7.7 MM, considerably less than 
the putative protective threshold of 11 MM typical of PiSZ 
patients.12 The primary function of AAT is protecting the 
lung from proteolytic enzymes, primarily neutrophil elastase 
(NE);13 in deficiency, uninhibited NE can therefore lead to 
lung damage via quantum proteolysis.14,15
Management of symptomatic lung disease is gener-
ally similar to usual COPD, including smoking cessation, 
inhalers, and pulmonary rehabilitation (PR).16,17 Infusion 
of plasma-derived AAT (augmentation therapy) to restore 
physiological levels is the only licensed disease-specific 
treatment and the only area studied by previous systematic 
reviews. Its use is variable worldwide, largely due to differing 
health systems, although controversy over efficacy exists.18,19 
A review by Chapman et al included many different study 
designs, focused on forced expiratory volume in 1 s (FEV
1
) 
as an outcome measure, and concluded that augmentation 
slowed FEV
1
 decline relative to placebo;18 however, FEV
1
 has 
limitations, meta-analysis of varied study designs could have 
flaws, and major trials have been published since. Cochrane 
considered only randomized controlled trials (RCTs) and 
reviewed more outcomes (FEV
1
, diffusing capacity of the 
lungs for carbon monoxide [DLCO], computed tomography 
[CT] density, and quality of life [QoL]), concluding that 
augmentation was not beneficial, due to a lack of effect on 
lung function and QoL.19 However, the benefit of measur-
ing lung density by quantitative CT scan analysis was that it 
relates to mortality in AATD,20,21 subsequently resulting in 
the review being criticized widely by specialists. As such, a 
new, more wide ranging review was indicated. In general, 
COPD meta-analyses demonstrating the impact of pharma-
cological and nonpharmacological interventions have been 
published,22,23 but most studies in usual COPD have excluded 
AATD patients, so the evidence may not be generalizable.
Methods
The systematic review protocol is registered with PROSPERO 
(CRD42015019354). Standard systematic review methodol-
ogy was used, aimed at minimizing bias, with reference 
to the Cochrane Handbook for Systematic Reviews of 
Interventions.24
Search strategy
The following databases were searched by using no date or 
language restrictions (Supplementary materials): MEDLINE, 
MEDLINE In Process and EMBASE (via Ovid), Cochrane 
Library (Wiley) CENTRAL, CDSR, HTA, EED, and DARE. 
In addition, Conference Proceedings Citation Index via Web 
of Science and British Library’s ZETOC were searched for 
conference proceedings and abstracts. ClinicalTrials.gov 
and World Health Organization International Clinical Trials 
Registry Platform were searched for ongoing trials. Refer-
ences of included studies and reviews were checked.
Study selection criteria
Figure 1 shows the selection criteria. Systematic reviews 
and primary study designs assessing treatment were eli-
gible provided they included data on 10 participants with 
AATD. Nonsystematic reviews and preclinical studies 
were excluded. Studies comprising mixed populations were 
permitted if AATD data were available separately. Any 
intervention for AATD-related lung disease was eligible for 
inclusion. The only restriction placed on outcome measures 
was of reporting 3 months after initiation of therapy, thus 
limiting to the most clinically relevant studies for this chronic 
disease. Studies which, for instance, measured solely AAT 
concentration before and after augmentation dosing were 
not included, and this criterion ensured such studies were 
not selected.
Data extraction and assessment of bias
Initial search yields (titles and abstracts) were screened for 
relevance by two reviewers independently, resolving any 
disagreement by discussion. Relevant articles were obtained 
and assessed against the full selection criteria, with transla-
tion of non-English language articles if required. Full-text 
articles were dually reviewed as before, with data extraction 
and bias assessment completed by one reviewer and checked 
by another. Missing data were requested from study authors if 
necessary (Supplementary materials). Reasons for excluding 
studies were documented and summarized in the PRISMA 
flow diagram (Figure 2).25
Evidence synthesis
Most data were suitable only for narrative synthesis, due 
to heterogeneity of study design and outcomes. Studies 
were divided into subgroups to reflect four “themes”: 
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AATD-specific, surgical, and medical treatments used in 
usual COPD, and other treatments. Data from three RCTs 
of AAT augmentation were meta-analyzed, the study 
design being sufficiently similar to allow this,26–28 including 
changes in lung density (measured by quantitative CT scan 
at least annually), FEV
1
 % predicted of normal, DLCO, QoL 
(St Georges Respiratory Questionnaire [SGRQ]), and annual-
ized exacerbation rate (measured at least 6 monthly). Assess-
ment of clinical and methodological heterogeneity was used 
to determine a fixed or random effect model; fixed effects 
using mean difference was appropriate in all but DLCO 
where a standardized mean difference was used. Differences 
between baseline and follow-up were synthesized and annual-
ized; I 2 and T2 statistics are reported where appropriate.
Results
Following the removal of duplicates, 7,296 records were 
reviewed with 52 trials, comprising 5,632 participants’ 
data included in the final analysis (Figure 2). The two 
systematic reviews identified were briefly described in the 
“Introduction” section and justified this new review; hence, 
they will not be discussed further. The complete study 
characteristics of the remaining studies are shown in the 
Supplementary materials.
AATD-specific treatment: augmentation
There were 26 eligible studies using a number of different 
product brands including Prolastin and Prolastin-C, 
Aralast, Zemaira, Trypsone, Respitin, and Glassia. Dosing 
regimes ranged from weekly to monthly with most using 
60 mg/kg/week.
RCTs
Three international multisite RCTs were identified,26–28 
including a total of 320 participants (5826–18028 per study), 
conducted over 2–3 years, with optional subsequent open-
label elements in two studies.27,28 All studies used CT density 
change as an outcome, two utilizing it as an experimental 
measure26,27 and one powering for CT density as the primary 
outcome (RAPID trial28). Other outcome measures included 
QoL, spirometry, and gas transfer and COPD exacerbation 
rates. Two studies used a standard dose (60 mg/kg body 
weight) intravenous infusion weekly,27,28 while the third used 
250 mg/kg infused every 4 weeks.26
Mortality data were only reported by RAPID28 with one 
death on treatment and three on placebo. Adverse events (AEs; 
treatment related or not) were similar in the two studies that 
reported them;27,28 one did not report AEs.26 The remaining out-
comes were possible to meta-analyze and are summarized in 
Figures 3 and 4. Heterogenicity was not detected (all I 20%). 
In all studies, volume-corrected CT scans at total lung capacity 
were performed, this being the preferred and most validated 
scanning method,27,29–31 though three scanning methods were 
reported in RAPID. Lung density was analyzed by regression 
in the study by Dirksen et al26 and RAPID28 with four analysis 
methods in EXACTLE.27 EXACTLE’s “method 1”27 was used 
Figure 1 PICO chart detailing inclusion in systematic review.
Note: PICO assessed are shown.
Abbreviations: AATD, alpha-1 antitrypsin deficiency; AAT, alpha-1 antitrypsin; Pi, protease inhibitor; COPD, chronic obstructive pulmonary disease; PICO, population, 
interventions, comparators, and outcomes.
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in this meta-analysis as it utilizes the same regression technique 
as other studies; sensitivity analyses using other EXACTLE 
methods did not alter the outcome or significance. Annual 
deterioration in lung density was less on augmentation; differ-
ence 0.79 g/L/year (95% confidence interval [CI] 0.29–1.29; 
P0.002, Figure 3), demonstrating a slower rate of emphysema 
progression. There was no significant difference in annual 
FEV
1
% predicted decline on treatment (0.56% predicted/
year [1.14–0.29; P0.20]). A small nonsignificant difference 
of 0.11 (0.33–0.11; P0.34) in DLCO was observed.
Annual exacerbation rate was not reported in the earli-
est study,26 but there was a small, statistically significant 
increase in annual exacerbations on treatment (0.29/year 
[0.02–0.54; P0.02], Figure 3) when meta-analyzing the 
other studies.27,28 Small and nonsignificant changes in health 
status were observed in both groups,27,28 demonstrating 
greater worsening in SGRQ on placebo 0.83 (3.55 to 1.89; 
P0.55, Figure 4).
Observational controlled studies
There were six eligible controlled observational studies, 
comprising 2,610 participants. AEs and reasons for starting/
stopping therapy were reported by one registry; severe events 
occurred at a rate of 9.5% (69/720 infusions).32
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Figure 2 PRISMA flow diagram.
Notes: Adapted from Moher et al.25 Articles were excluded where there were insufficient data in the public domain for the study to be assessed against the inclusion criteria 
including data from ClinicalTrials.gov.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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The largest observational study analyzed data from 
1,129 patients in the US AATD registry split into three groups 
“always receiving” (n390), “partly receiving” (n357), or 
“never receiving” (n382) augmentation.33 Dosing was not 
standardized with only 51.3% being dosed weekly throughout 
the study. A survival analysis was conducted, but excluded 
81 subjects (55 deaths) due to missing data, such that results 
could have been biased. Overall mortality was 18.1% 
(n204); it was significantly higher for subjects who never 
received augmentation therapy (as opposed to sometimes or 
always) when FEV
1
50% predicted (P0.001). Mortality 
rates were low for other subjects and did not differ between 
augmentation therapy groups. FEV
1
 decline was calculated 
using a slope equation in 927 patients with n202 excluded 
due to insufficient data; patients receiving augmentation with 
mean FEV
1
 values of 35%–49% predicted had a slower rate 
of FEV
1
 decline (73.7o6.8 vs 93.2o8.9; P0.03), though 
this was not seen in the whole group.
Three other studies investigated the effect of AAT 
augmentation on FEV
1
 decline.34–36 Seersholm et al34 
undertook a nonrandomized surveillance study in two 
cohorts. A statistically significant difference in FEV
1
 annual 
decline was observed (53 [48–58] vs 75 [63–87] mL/year 
in treatment vs placebo; P0.02).34 The other two studies 
concurred with this result. Wencker et al conducted a pre–
post study of augmentation, using inclusion criteria of 2 
lung function measurements prior to augmentation and two 
following commencement of therapy within a minimum 
period of 12 months.36 FEV
1
 declined significantly slower 
(34.3o29.7 vs 49.2o60.8 mL/year, P0.019) after starting 
augmentation. Tonelli et al compared 124 augmented PiZZ 
patients to 40 nonaugmented patients who had a median 
of two spirometry measurements over a mean follow-up 
of 41.7o2.6 months.35 Again, FEV
1
 decline was worse in 
untreated patients (10.61o21.4 vs 36.96o12.1 mL/year; 
P0.05). All three studies stratified patients to groups by their 
FEV
1
 at presentation – FEV
1
30%, 30%–65%, and 65% 
predicted.34–36 Patients with FEV
1
30% were consistently 
observed not to benefit from augmentation in terms of 
FEV
1
 decline. Two of the three studies showed those with 
an FEV
1
65% to have statistically significant reductions 
in FEV
1
 decline when on augmentation (122.5o108.4 
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Figure 3 Forest plots of the objective results from meta-analysis of augmentation trials.
Notes: (A) Mean annual change in lung density. (B) Mean FEV
1
 % predicted. (C) Standardized mean difference in DLCO. Differences in units used for DLCO (mmol/min/kPa 
and mL/mmHg/min) and the use of percentage change from baseline in RAPID, but annual change in the other studies required the use of a standardized mean difference plot.
Abbreviations: FEV
1
, forced expiratory volume in one second (L); DLCO, diffusing capacity of the lungs for carbon monoxide; mmol/min/kPa, millimole per minute per kilopascal; 
mL/mmHg/min, milliliter per millimeter of mercury per minute; SD, standard deviation; CI, confidence interval; df, degrees of freedom; Std, standard; IV, inverse variance.
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vs 48.9o54.9 mL/year; P0.045 and 108.7o17.3 
vs 29.2o15.29 mL/year; P0.0006).35,36 Treatment effect was 
restricted to patients with FEV
1
30% and 65% (62 [57–67] 
vs 83 [70–96] mL/year; P0.04) in one study.34 When FEV
1
 
at commencement of therapy was used to group patients, a 
statistically significant decrease of rate of decline during 
treatment was seen if FEV
1
30% (53.4o45.3 to 22.1o16.0 
mL/year; P0.0001).36 Subgrouping the FEV
1
65% group 
demonstrated marked benefit in those deemed rapid decliners 
(FEV
1
 decline pre- vs postaugmentation 255.7o70.4 vs 
52.7o61.3 mL/year; P0.0016).
The most recent study by Barros-Tizon et al37 was a 
retrospective medical records review of 127 participants 
evaluating the effect of augmentation on exacerbation 
rate. Seventy-five patients had 1 exacerbation during the 
18 months follow-up required prior to commencement of 
augmentation. Dosing regimens were not standardized with 
an average dose of 60.7o3.8 mg/kg/week (Table S1) different 
from other studies,33 and many patients had missing data. 
Fewer exacerbations were seen (1.2o1.6 vs 1.0o2.2 pre- vs 
posttreatment; P0.01), an effect more marked in those 
exacerbating previously (2.0o1.6 vs 1.4o2.7; P0.01).
Controlled studies of differing dose 
and/or drug manufacturer
Five RCTs38–42 with 176 participants investigated differences 
between dosing regimens of a product38 or made compari-
sons between different products.39–42 Campos et al38 used a 
double-blind crossover study of 60 versus 120 mg/kg/week 
of Prolastin-C to investigate safety and pharmacokinetics 
in 30 patients. They reported no increase in AEs, a higher 
trough serum AAT concentration, and that the higher dose 
was tolerated well by patients. Four double-blind RCTs39–42 
completed investigating pharmacokinetic equivalence 
between weekly dosing of the new investigational product 
(Respitin,42 Zemaira,41 Prolastin-C,39 and Glassia40) and 
control (60 mg/kg/week Prolastin). All the studies had 
an optional open-label continuation study for safety data 
collection (ranging from 8 weeks39 to 2 years41) and reported 
no significant difference in AEs between the investigational 
product and control. Pharmacokinetic equivalence was 
reported in all studies with none demonstrating superiority 
over Prolastin. Stoller et al,42 and Sandhaus et al40 reported no 
significant differences in lung function parameters between 
the investigation groups or over the duration of the studies. 
One death was reported (respiratory arrest related to COPD) 
in the study by Stocks et al,41 which was in the control arm 
and considered unrelated to study medication.
Observational uncontrolled studies
Twelve uncontrolled observational studies using intravenous 
AAT augmentation in 2,526 patients were included, which 
assessed safety and tolerability,43–45 pharmacokinetics,46–48 
pulmonary neutrophilic inflammation,49 longitudinal change 
in lung function,50–52 and clinical characteristics or 
recipients.53,54 AAT augmentation was reported as safe and 
well tolerated (one study drug-related AE out of 555 doses)45 
with 26 AEs probably/possibly related to the study drug,43,45,47 
largely comprising symptoms commonly observed in 
infusions of other protein-based products.52 Other adverse 
reactions reported43,49 were one widespread skin reaction,49 
headache and increased shortness of breath, and hospital 
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Figure 4 Forest plots for patient-reported outcomes.
Notes: (A) Annual patient-reported exacerbation episodes. (B) Health status: SGRQ, measures recorded as change from baseline.
Abbreviations: SGRQ St Georges Respiratory Questionnaire; SD, standard deviation; CI, confidence interval; df, degrees of freedom; IV, inverse variance.
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treatment for fever, hypotension, and hypoxemia.43 In all, 
61 of 2,526 patients died with none attributed to AAT 
augmentation.46,51,52 Augmentation was again well tolerated 
and deemed safe in a small study of 60 mg/kg/week versus 
240 mg/kg/month.50
Biochemical efficacy at the higher dose given monthly 
did not demonstrate a protective AAT level in 3 of 16 
patients.50 A second study investigating the pharmacoki-
netics of an alternative dose (Prolastin, 120 mg/kg every 
2 weeks) was completed in 23 participants;46 none of the 
patients maintained target serum AAT levels (80 mg/dL) 
and only two maintained serum AAT levels 70 mg/dL 
from days 7 to 14 suggesting insufficient dosing. Wewers 
et al47 included 21 patients infused weekly for up to 6 months 
and demonstrated partial correction of biochemical abnor-
malities in serum (AAT trough level 126o1 vs 30o1 mg/dL) 
and pulmonary epithelial lining fluid (AAT 0.46o0.16 
vs 1.89o0.17 MM). Similarly, effective concentrations of 
AAT were reported by two short-term studies43,44 and one 
3-year study.51 A study investigating 18-fluorodeoxyglucose 
(18FDG) positron emission tomography–CT as a novel 
noninvasive biomarker49 had a subgroup of 10 patients with 
severe AATD. The study demonstrated that 12 weekly infu-
sions of AAT augmentation therapy had no effect on circulat-
ing neutrophil 18FDG uptake and activity in the lung.
Pulmonary function was reported in five studies with no 
significant changes in rates of decline or spirometry being 
observed.46,47,50–52 An observational registry study where 
longitudinal FEV
1
 follow-up was available in 287 patients 
over 37.8o18.9 months showed significant differences in 
decline in FEV
1
30% predicted and FEV
1
 30%–65% groups 
(35.6o21.3 vs 64.0o26.4 mL; P0.0008).52
AlphaNet in USA is a not-for-profit health management 
company, which undertook a prospective study involving 
922 members on augmentation, using monthly telephone 
interviews to collect data including exacerbation history 
and QoL (SGRQ) at baseline, months 6, and 12.53 Totally, 
2,268 exacerbations (mean 2.45o1.3/subject/year) were 
observed, mostly graded to be of moderate severity. SGRQ 
did not change by the minimal clinically important difference 
(MCID) during the 12-month follow-up in any age group, 
though differences were seen according to age. The same 
cohort was used54 to describe exacerbations in more detail. 
Mean duration was 17.4o11.4 days by symptom-based clas-
sification, with a trend for increasing frequency and duration 
as disease severity increased; Global initiative for chronic 
Obstructive Lung Disease (GOLD) stage I and II patients 
had shorter, fewer exacerbations than GOLD stage III and 
IV (both P0.05). Annual hospitalization for exacerbations 
was decreased in 4/14 patients in one study where study entry 
annual rates were used to assess augmentation; however, the 
study was insufficiently powered to establish the effective-
ness in modifying disease.43
COPD medical management
There were only two eligible studies in AATD using tradi-
tional COPD medical management strategies.17,55 The first 
reported good uptake and efficacy of influenza vaccination 
in the AlphaNet cohort (n939),55 with 766 (81.6%) patients 
receiving vaccination, who then had fewer unscheduled out-
patient department visits and critical care admissions (P0.04 
and 0.01, respectively). No statistically significant differ-
ences in exacerbation frequency or respiratory outcomes 
were observed. Another observational study by AlphaNet 
investigated the use of a multimodal self-management pro-
gram with a combination of directed patient self-education, 
organized supervision, and health care provider education 
(Alpha-1 Disease Management and Prevention Program) in 
1,028 participants.17 This 2-year study used data from the first 
“observational” year as comparator to a second year when the 
management plan was delivered. A total of 905 participants 
completed the 2 years demonstrating low attrition. There was 
strong evidence to support improved compliance in some 
medications (long-acting beta agonist [LABA] P0.001, 
theophylline P0.01, and systemic steroids P0.02) and 
supplementary oxygen (P0.01) along with reductions in 
annual exacerbation frequency and duration (P0.001 and 
P0.04, respectively). There were no significant changes to 
health status.
COPD surgical management
Lung volume reduction (LVR)
Six studies investigated the use of Lung Volume Reduction 
Surgery (LVRS) in AATD. Five studies (n71 patients) 
used an open surgical technique,56–60 and all demonstrated 
improvements in either physiological measurements or dysp-
nea. Benefits were inferior and shorter in duration than usual 
COPD patients in all studies. One small RCT randomized par-
ticipants to LVRS (n10) or medical treatment (n6); higher 
2-year mortality (20% vs 0%) occurred in the surgical group, 
albeit alongside improvements in SGRQ.59 There was one 
published study using endobronchial valves, which demon-
strated their safety in AATD patients with significant benefits 
in mean FEV
1
 at 6 months, 1, and 2 years (P0.0022, 0.0067, 
and 0.033, respectively).61 The generalizability of this study 
is not evident as this cohort included strict inclusion criteria 
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including severe heterogeneous emphysema demonstrated by 
CT scan and scintigraphy, residual volume 140%, FEV
1
 
15%–45%, and optimal lobe selection. This resulted in fewer 
than half of the referrals meeting these criteria.61
Lung transplantation
Eleven studies over 24 years reported 2,146 lung transplants 
in AATD patients.62–72 Two studies investigated survival 
after transplantation compared with nontransplantation 
management; Tanash et al71 observed a survival benefit 
from transplant (11 [9–14] vs 5 [4–6] years; P0.006). 
No significant difference was observed in survival (10.1 
vs 8.4 years; P0.954); however, improvements in total 
SGRQ (and all domains) were seen at 1 year (P0.01).72 
Six studies64–69 using retrospective reviews of lung trans-
plant registries (all cause, not specific to AATD) con-
tained sufficient separately reported data on mortality. 
Two demonstrated superior 10-year survival in AATD 
patients compared to usual COPD (P0.04 and P0.0001, 
respectively),67,68 but both noted that COPD recipients were 
often older with greater comorbidity. Conversely, Breen 
et al observed higher patient survival at 2 years in usual 
COPD (75.4%o4.4% vs 64.4%o5.4% in AATD); however, 
insufficient power precluded statistical analysis.64 All other 
studies showed no difference in long-term survival between 
AATD- and non-AATD-related COPD.62,65,66,69,70 
There were some studies that reported other posttransplant 
outcomes. A subgroup analysis of patients receiving 
bilateral lung transplants demonstrated faster posttransplant 
FEV
1
 decline in AATD patients (P0.002).62 Analysis 
of gastrointestinal complications posttransplant surgery 
showed that having AATD significantly increased the risk 
of requiring early postoperative laparotomy (odds ratio 5.74, 
95% CI 2.15–15.35), which increased all-cause mortality by 
62% (P0.05).63
Other management
A double-blind, parallel-group RCT of Palovarotene to 
reduce inflammation and promote structural repair in the 
lungs failed to demonstrate significant differences in change 
from baseline for CT density, FEV
1
, or gas transfer measures 
and exacerbation.73
Unreported trials
A study of an inhaled AAT augmentation therapy 
(NCT01217671) is listed as completed, but limited data are 
currently available.74,75 One registered study (NCT00242385)76 
compared two augmentation products in a double-blind, 
crossover RCT. Only one outcome (AEs) was eligible for 
inclusion as follow-up for all other outcomes were limited to 
35 days; similar safety profile and no serious AEs were seen, 
but no statistics were available. A second study compared two 
Prolastin-C levels at 60 and 120 mg/kg to assess safety and 
pharmacokinetics (NCT01213043).77 No statistical analysis 
was available but 30 participants completed the study with 
similar treatment-emergent AEs and safety profile to other 
studies; no serious AEs occurred. There is currently one study 
(NCT01983241)78 investigating 60 and 120 mg/kg weekly 
administrations of Prolastin-C against placebo to determine 
safety and efficacy using change from baseline in CT lung 
density as the primary outcome.79
Risk of bias
Risk of bias for the meta-analyzed RCTs is summarized in 
Figure 5A. Risk of bias in RAPID28 was low; however, in the 
two earlier augmentation studies, this was more difficult to 
assess and generally unclear due to poor reporting, specifi-
cally of details such as allocation concealment. The other 
six RCTs demonstrated low or unclear bias, mostly due to 
lack of detail in the manuscripts, commonly around blinding. 
Figure 5B summarizes the risks in the remaining studies. The 
mixture of RCTs and cohort and observational studies (both 
prospective and retrospective) led to an overall moderate risk 
of bias especially in the nonblinded studies. In the controlled 
or quasi-controlled studies, there was often insufficient 
reporting of the blinding process and allocation concealment, 
except in more recent studies, and a trend toward selective 
outcome reporting.18,36,38 Within the uncontrolled retrospec-
tive studies, selection bias was the main issue, with patients 
being taken from self-selecting groups or registries. Trans-
plant studies from registries suffered from high attrition rates, 
which may have introduced survivor bias.64–69
Discussion
The available evidence for the management of AATD was 
largely centered on augmentation, which seemed to benefit 
emphysema, but with significant deficits in the evidence 
base for outcomes more typically assessed in COPD studies, 
such as exacerbation frequency and QoL. Although it is not 
unreasonable to think that strategies used to treat COPD 
unrelated to AATD could be extrapolated to AATD patients, 
there was almost no evidence proving this.
Augmentation
Augmentation was demonstrated to be safe and well tolerated 
in numerous studies using different products. Investigations 
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into dosing regimes demonstrated few benefits from 60 mg/ 
kg/week38 (the “standard” dose), and pharmacokinetic 
equivalence was observed between different manufacturers’ 
products.40,41 
The meta-analysis confirmed that augmentation therapy 
is able to slow down the progression of severity of emphy-
sema when measured by CT density change compared 
with placebo (P0.002). By combining data from up to 
320 patients included in three RCTs, it adds to an increas-
ing body of literature demonstrating the usefulness of CT 
densitometry as a surrogate measure of emphysema and 
outcome in both AATD and usual COPD.20,80,81 However, the 
MCID has not yet been established for change in CT density, 
which would be helpful for interpretation. Meta-analysis also 
revealed a small but significant increase in annual exacerba-
tion rate on augmentation. This is somewhat counterintuitive 
and contradicted by studies included in narrative synthesis, 
which either showed a benefit or no significant difference 
in exacerbation rate or severity.17,37,54 Increased contact with 
health care professionals, simply due to attending for infu-
sions, could lead to increased reporting of exacerbations, 
but this is the opposite result from published observational 
studies. These findings require caution in their interpreta-
tion as none of the studies were powered to detect change 
in exacerbation rates as an outcome. Studies in usual COPD 
appropriately powered to detect change in exacerbation 
frequency often require several thousand patients.82 With 
advances in technology and a reduction in the cost of digital 
patient symptom diaries, there are an increasing number of 
studies using them to collect contemporaneous symptom 
data, including a recent inhaled augmentation therapy 
(NCT01217671) trial.75 This has been beneficial in usual 
COPD trials83,84 as it avoids recall bias and gives accurate 
data on severity and duration; hence, the results will be of 
interest. The Spanish study that focused on exacerbations 
had issues with missing data and also used variable treat-
ment regimens, such that bias and lack of comparability to 
RCTs are an issue.37 There are several other reasons why 
the exacerbations result should be viewed with caution; first, 
prestudy exacerbation frequency was not reported in the 
three RCTs. Prior exacerbation rate predicts future exacerba-
tion rate;85,86 hence, if a difference was present pretreatment, 
it could account for the observation posttreatment. Second, 
power calculations were not based on detecting change 
in exacerbation frequency. Nevertheless, this area will be 
important for further study because faster decline in lung 
function and significantly increased health care costs occur 
due to frequent exacerbations in usual COPD,87,88 an effect 
that might be more marked in AATD due to higher inflam-
matory burden during events.89 
Most observational controlled studies demonstrated 
some differences in FEV
1
 decline with recipients of 
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Figure 5 Risk of bias in included studies.
Notes: (A) Risk of bias in augmentation RCTs. (B) In view of the large number of studies and the differing scales for assessment of risk based on the study design, a summary 
of the relative risk of bias is shown across all included studies, other than the RCTs of augmentation. This represents review authors’ judgments about each risk of bias item 
presented as the mean percentage across all included studies. Individual bias assessments are available in the Supplementary materials.
Abbreviation: RCT, randomized controlled trial.
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AAT augmentation benefiting over those not receiving 
therapy.34,35,52 However, such study designs have weaknesses, 
often relating to differences between treated and untreated 
groups. For instance, sex, FEV
1
, and follow-up time differ-
ences were seen between treated (German) and untreated 
(Dutch) patients,34 and age, FEV
1
, symptoms, inhaled thera-
pies, and oxygen use differed in another study35 indicating 
that biases are likely present, which could have influenced 
results. In most cases, attempts were made to adjust for 
major differences statistically when comparing groups, and 
subgroup analyses suggested that benefits did not accrue in 
patients with FEV
1
30% predicted. However, since it has 
been demonstrated that gas transfer declines more rapidly 
at this stage,86 it may simply be that different outcome mea-
sures were needed to demonstrate any effect. In one study, 
there was evidence that rapidly declining patients benefited 
more;52 however, there were only 11 such patients, and the 
definitions of slow and rapid decline utilized are not widely 
adopted in practice.
COPD medical management
There was limited evidence about the efficacy of COPD 
treatments in AATD, and no trials reported the effects of 
typical treatments such as inhaled bronchodilators (long act-
ing muscarinic antagonist, LABA, etc), steroid combinations 
(LABA/inhaled corticosteroids [ICS]), or PR. The available 
evidence was of poor quality, being prone to acquisition and 
potentially other biases, due to its retrospective, observational 
design. However, the results for influenza vaccination and 
self-management were at least suggestive of clinical benefit 
to AATD patients, thus consistent with the usual COPD 
literature.22 There is no biological reason to suppose that 
such interventions would differ in efficacy between usual 
COPD and AATD.
However, data from the uncontrolled studies54 and sputum 
work89 suggest that exacerbations are longer and more pro-
inflammatory in AATD, such that treatments targeting their 
rate (eg, LABA/ICS) might be more beneficial in AATD. 
Recently, an unfavorable muscle response to exercise has 
been shown in a small number of AATD patients, compared 
with usual COPD,90 suggesting that evidence about PR might 
not be wholly generalizable to AATD either. This is backed 
up by a study of a 5-week PR program pretransplantation, 
where AATD patients were observed to have a smaller 
improvement in 6-min walking test distance compared with 
usual COPD (47.9 vs 60.6 m).91 However, the PR course 
was short, and the study was not eligible for inclusion in 
this review due to short follow-up duration; furthermore, 
no difference was seen after statistical adjustment for 
confounders. Hence, uncertainty exists about the value of 
COPD treatments, and further work is needed.
COPD surgical management
AATD patients receiving LVRS demonstrated benefits, 
albeit inferior when compared with usual COPD. In the 
single study, compared to medical care (as in the National 
Emphysema Treatment Trial study), there were more 
deaths in surgically treated patients, even though their QoL 
improved. However, underpowering meant there were no 
meaningful statistics and the results should be viewed with 
caution. Higher mortality could reflect differences in the dis-
tribution of emphysema in AATD, making LVRS technically 
more difficult because access to the lung bases is needed.92 
One small study demonstrated safety and benefits lasting up 
to 2 years from endobronchial valves in carefully selected 
patients – further investigation to reproduce these findings 
is warranted; however, it is encouraging and suggests that 
volume reduction might yet be a viable strategy. There is 
no evidence for endobronchial coiling in AATD yet, though 
suggestion of benefit in more homogeneous disease93 implies 
they could be valuable.
When compared to usual COPD, AATD lung trans-
plantation recipients had improved survival, but this was 
potentially confounded by differences in age and comor-
bidity.68 Earlier onset of severe disease is well documented, 
and therefore, a survival benefit posttransplant may not be 
surprising. Two studies comparing AATD patients receiving 
transplant or not71,72 had conflicting results with respect to 
survival benefit, despite selection criteria for transplanta-
tion being similar in both countries (Sweden and UK). It 
is possible that more stringent matching procedures in the 
UK cohort72 explain the difference. Nevertheless, significant 
health status benefits occurred after transplant indicating 
that it is appropriate when QoL is poor. However, unlike 
pulmonary fibrosis where there is unified evidence of sur-
vival benefit (in part due to the poor prognosis of disease),94 
uncertainty regarding survival benefits should be discussed 
with patients and is not only unique to AATD but also appar-
ent in usual COPD and may represent the heterogeneity of 
disease.94 The single study that demonstrated decline in 
AATD transplant recipients included only five patients and 
a time frame (2 years) for the calculation of FEV
1
 decline, 
which is too short to be accurate; hence, the results may 
not be reliable.62 Increased posttransplant gastrointestinal 
complications requiring laparotomy were demonstrated in 
one study63 with those patients having a longer intensive 
care unit stay. There was no statistically significant effect 
on mortality or duration of mechanical ventilation observed, 
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and the authors note that this was a small single-center 
retrospective study.
Conclusion
There is good evidence from this systematic review that intra-
venous augmentation therapy slows decline in emphysema 
determined by CT density. This supports its use as a surrogate 
end point and demonstrates that augmentation remains the 
primary disease-specific therapy. There is paucity of data 
around other treatments in AATD including potential bias in 
the selection and reporting of clinical trials. As augmentation 
therapy is an expensive treatment, a full economic review is 
needed, and further work on optimizing patient selection for 
therapy could help rationalize treatment in the UK. All treat-
ments for usual COPD may not be as efficacious in AATD 
due to important differences in disease process, and studies 
in specific treatments such as PR need to be appropriately 
powered to this disease group.
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